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with PK observations. The Modufolin® to Isovorin® Cmax 
ratio for methyleneTHF was 113 at 200 mg/m2 and 52 at 
60 mg/m2; the AUClast ratios were 17 and 9, respectively. 
The THF plasma concentrations were also higher after 
Modufolin® administration (Cmax ratio 23, AUClast ratio 13 
at 200 mg/m2; Cmax ratio 15, AUClast ratio 11 at 60 mg/m2).
Conclusion Modufolin® administration resulted in sig-
nificantly higher methyleneTHF levels than Isovorin® and 
may potentially increase the efficacy of 5-fluorouracil-
based chemotherapy. The results encourage further evalu-
ation of Modufolin® as a substitute to Isovorin® including 
the potential clinical benefits.
Keywords Colon cancer · 5-FU-based chemotherapy · 
Levo-leucovorin · Methylenetetrahydrofolate · CH2THF · 
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Introduction
Folates are naturally occurring forms of the soluble vita-
min B9. They are fundamental to the cell by serving as 
one-carbon donors in the synthesis of purines and the 
pyrimidine deoxythymidine monophosphate (dTMP) [1]. 
Imbalance of the folate metabolism is suggested to affect 
several cellular processes, as folates are vital both for 
DNA synthesis and repair, as well as gene regulation by 
DNA methylation. Intracellular reduced folates exist as a 
pool of several interconvertible forms, which are involved 
at different stages in folate dependent and interconnected 
metabolic pathways (Fig. 1). The understanding of the 
underlying mechanisms with respect to transport, commu-
nication, and regulation among these metabolic pathways 
and networks is still incomplete and under investigation 
[2–4].
Abstract 
Purpose Leucovorin is commonly used as folate sup-
plement in 5-fluorouracil-based chemotherapy, but needs 
to be converted to active 5,10-methylenetetrahydrofolate 
(methyleneTHF) intracellularly. This provides for inter-
individual differences. MethyleneTHF has recently been 
developed into the stable, distributable drug, Modufolin®. 
The aim was to compare the concentration of folate metab-
olites in tumor, mucosa, and plasma of patients with colon 
cancer after administration of Modufolin® or Isovorin® 
(levo-leucovorin).
Methods Thirty-two patients scheduled for colon resec-
tion were randomized to receive Modufolin® or Isovorin® 
at dosage of 60 or 200 mg/m2. The study drug was given 
as one i.v. bolus injection after anesthesia. Plasma was col-
lected for pharmacokinetic (PK) analysis before, during, 
and after surgery. Tissue biopsies were collected at surgery. 
Folate metabolites were analyzed by LC-MS/MS.
Results MethyleneTHF and THF concentrations were 
significantly higher in mucosa (p < 0.01, both dosages) and 
tumors (p < 0.01, 200 mg/m2) after Modufolin® as com-
pared to Isovorin® administration. The results correlated 
This study was registered at ClinicalTrials.gov (NCT No. 
01681472) and ClinicalTrialsRegister.eu (EudraCT No. 2012-
000522-22).
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Folates can be used to modulate the action of the com-
monly used drug 5-fluorouracil (5-FU) [5, 6]. The origi-
nal response rate of 5-FU in colorectal tumors, given as a 
monotherapy, was only around 10 %. By adding the stable, 
reduced form 5-formyltetrahydrofolate (formylTHF) i.e., 
leucovorin (LV), the tumor response rate was improved to 
21 % as shown in a meta-analysis [5]. Intracellularly, LV 
needs to be converted to the active metabolite 5,10-methyl-
enetetrahydrofolate (methyleneTHF). This metabolite then 
forms a ternary complex with deoxyuridine monophosphate 
(dUMP) and the target enzyme thymidylate synthase (TS) 
in a reaction where dUMP is converted to dTMP [6, 7]. 
The reaction is inhibited when the fluorinated metabolite of 
5-FU, FdUMP, binds the complex instead of dUMP [8, 9].
Thus, LV has no antitumoral effect on its own, but enhances 
the effect of 5-FU by providing methyleneTHF in abundance, 
which stabilizes the ternary complex [10]. The inhibition of 
TS impairs production of dTMP needed both in DNA syn-
thesis and DNA repair. The inhibition will have most impact 
on cells with a high proliferation rate, such as tumor epithelial 
cells. As a consequence, the DNA synthesis in the cells is sup-
pressed which may lead to cell death due to apoptosis. Insuf-
ficient cellular levels of methyleneTHF could be an important 
factor behind the lack of TS inhibition during 5-FU chemo-
therapy. An enhanced 5-FU effect would reduce the required 
quantities of toxic metabolites and, thus, the toxic side-effects 
during treatment would theoretically be less. The pharmacoki-
netics of LV metabolites as a function of intravenously given 
dosage has been described by Priest et al. [11].
The need for metabolic activation of LV could provide 
for interindividual differences in its utilization that could 
affect the potential benefit gained from the LV addition. 
Previous results, including findings of our own research 
group [12], have showed that the variation in folate levels 
in tumor and mucosa tissues between patients is signifi-
cant. The continued advances in genetics and metabolomics 
provide new possibilities for advanced studies of the folate 
metabolism and enables greater understanding of the inter-
play between folates and enzymes targeted by different 
chemotherapeutic drugs.
As methyleneTHF is the only natural folate that directly 
binds the ternary complex, its usage could have advantages 
compared to LV. However, as a substance, it is very sensi-
tive to oxidation. The stability, production, and administra-
tion issues have recently been resolved and methyleneTHF 
has been developed into the stable drug Modufolin®. The 
aim of the present study was to gain an understanding of 
how a single bolus injection of Modufolin® affects the con-
centration of different folate metabolites, including methyl-
eneTHF, in tumor tissue, adjacent mucosa, and plasma as 
compared to Isovorin® (levo-leucovorin) in patients with 
colon cancer using a highly sensitive liquid chromatog-
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Fig. 1  A simplified overview of the folate metabolism. Within the 
cells, Modufolin® (5,10-methyleneTHF) can be used directly as a 
methyl donor in the synthesis of dTMP from dUMP. The reaction is 
catalyzed by the enzyme thymidylate synthase (TS). Isovorin® (5-for-
mylTHF), on the other hand, needs to be converted in two steps to 
methyleneTHF. Treatment with 5-FU inhibits the synthesis of dTMP 
through the formation of FdUMP, which binds TS. DHF dihydro-
folate, DHFR dihydrofolate reductase, SHMT1 serine hydroxym-
ethyltransferase 1, MTHFR methylenetetrahydrofolate reductase, 
MTHFD methylenetetrahydrofolate dehydrogenase, MTHFS methe-
nyltetrahydrofolate synthetase
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Hospital/Östra, Gothenburg, Sweden). Between September 
2012 and July 2013, 32 patients scheduled for colon resec-
tion due to colon cancer were screened and asked for partic-
ipation. The main inclusion criteria were: Age ≥18 years, 
ECOG performance status of 0–1 and resectable colon can-
cer/curative intent of surgery, whereas the main exclusion 
criteria were: Concurrent other antitumor therapy, other 
malignant disease, severe systemic disease, or medications 
which could influence homocysteine, folate, and vitamin 
B12 status, within 30 days of surgery. All included patients 
provided written informed consent. The study was done in 
accordance with the Declaration of Helsinki and adhered to 
the ICH Good Clinical Practice Guidelines. The protocol 
complied with local regulations and was approved by the 
Institutional Review Board and the Swedish National Com-
petent Authority, Medical Products Agency (MPA). The 
study was also approved by the Regional Ethics Committee 
in Gothenburg (EPN).
Randomization and masking
Included patients were randomly assigned (in a 1:1:1:1 
ratio, with a block size of eight) to receive either Modu-
folin® or Isovorin® at a low (60 mg/m2) or high (200 mg/
m2) dosage. Treatment group assignment was based on a 
computer-generated randomization list. Assignment to 
treatment was done in a consecutive order by means of 
randomization envelopes, which were opened by the study 
nurse preparing the study drug at the time point of study 
drug administration. The patient’s study identification 
number was used on the electronic case report form and as 
identifier on all samples.
The patients and the study team were masked with one 
exception; it was not possible to mask the study drug to the 
study nurse who prepared the bolus injection. The reason 
for this was that Modufolin® is provided as a powder for 
injection that needs to be reconstituted in saline in connec-
tion with administration, whereas Isovorin® is provided as 
a solution for injection. After reconstitution, Modufolin® 
has a similar appearance as Isovorin®. However, all other 
involved study personnel were masked. The statistical and 
clinical study teams at the sponsor remained masked during 
the study. The study code was broken after declaration of 
clean file and database lock.
Design and aim
The patients received one i.v. bolus injection of study drug 
after being anesthetized for surgery. Plasma samples were 
collected for pharmacokinetic (PK) analysis 5–20 days 
before surgery and on the day of surgery (after anesthetics 
and immediately prior to study drug administration) as well 
as 5, 10, 20, 40, 60, 90, 120, 180, 240, and 360 min after 
study drug administration. Plasma samples were also taken 
the day after surgery; at 24 h. End of study assessments 
were made 5 ± 2 days after surgery. A complete physical 
evaluation was done at inclusion and again at end of study 
participation. Adverse events (AEs) were assessed con-
tinuously to monitor safety aspects. The primary endpoint 
was tissue (tumor and adjacent mucosa) concentrations of 
methyleneTHF, THF, methylTHF, and formylTHF. Second-
ary endpoints consisted of PK parameters based on plasma 
concentrations of the same metabolites and correlations 
between plasma and tissue concentrations.
Samples and handling
Biopsies from tumor and adjacent mucosa were collected 
during surgery. The macroscopically normal-appearing 
mucosa samples were taken at a distance of approxi-
mately 10 cm from the tumors. All samples were accrued 
in a standardized manner by dedicated research nurses. 
The actual biopsy collection time point and the time 
point when the circulation to the tumor was stopped were 
recorded. The time point for biopsy collection in relation 
to study drug administration and circulation stop time var-
ied between patients due to individualized surgery pro-
cedures. The biopsy samples were snap-frozen in liquid 
nitrogen and stored at −80 °C until analyzed. Each sam-
ple was divided into several vials in order to avoid repeated 
freezing and thawing. The tissue concentrations of methyl-
eneTHF, THF, methylTHF, and formylTHF were measured 
using an LC-MS/MS method as described previously [13]. 
To check for degradation of the four analytes, the intra- and 
interbatch variability was determined in tissue Q samples 
at low, medium, and high concentrations on the same day 
and over 5–8 days. The relative intra-batch standard devia-
tion ranged from 4.8 to 10.2 % for all analytes, whereas 
the interbatch variability ranged from 4.9 to 20 %, with the 
highest variability found for methyleneTHF at the low Q 
sample concentration.
Plasma was obtained from the patients’ arm that was not 
used for study drug administration as close to the predefined 
time points as possible. The exact time points were recorded 
in the eCRF. Nominal sampling times were used for PK cal-
culations as deviations from actual values were considered 
to be small (generally within ±20 %). A few time points 
in the beginning of the sampling period after dosing devi-
ated >20 %, but this was considered to have small impact 
on the PK calculation outcome. The plasma samples were 
frozen, stored, and shipped at −80 °C to Charles River Lab-
oratories, UK, where the plasma concentrations of methyl-
eneTHF, THF, methylTHF, and formylTHF were analyzed 
using a validated LC-MS/MS method. In brief, samples 
were separated and quantified using a Poroshell 120 EC-
C18 column (Agilent Technologies). The mobile phase 
40 Cancer Chemother Pharmacol (2015) 75:37–47
1 3
consisted of a variable mixture of A (acetonitrile/formic 
acid), and B (water/formic acid) with a flow rate of 0.5 ml/
min. The autosampler temperature was set to 4 °C and the 
column maintained at 60 °C. Transitions for analytes and 
13C5-labelled internal standards were as shown in Table 1. 
Quantitation was done by comparison to a 9-point calibra-
tion curve (100–10,000 ng/ml) using the ratio of the analyte 
response to the internal standard plotted against the analyte 
injected. The mass spectrometer was run in the negative 
MRM mode. The reinjection stability was found to be 52 h 
for methyleneTHF, THF, and formylTHF, and 7 days for 
methylTHF, at 4 °C. Both tissue and plasma analyses were 
performed batch-wise.
Statistical analysis and considerations
This was an exploratory proof of concept study, and the 
number of patients chosen was based on practical consid-
erations and not on a statistical power calculation. Statistical 
analyses were done with SAS version 9.3 or JMP 10.0 (SAS 
Inc, Cary, USA). The significance level was set at 0.05.
An exploratory evaluation of the primary endpoint, 
i.e., tumor and mucosa concentrations of methyleneTHF, 
THF, methylTHF, and formylTHF was done, respectively, 
for differences between treatments using analysis of vari-
ance. The same evaluation was done for the secondary 
endpoint, PK parameters, in plasma. It was found that the 
assumptions of normality were violated, and therefore non-
parametric methods (Proc GLM and Levene’s test) were 
applied to determine differences in variability between the 
treatment groups. The Kruskal–Wallis and Wilcoxon two-
sample test (two-sided) were used to compare differences 
between treatments.
The PK/pharmacodynamic (PD) analyses were done 
including all patients who completed the trial with-
out any major deviations from the protocol procedures. 
All included patients who received trial medication and 
from whom at least one measurement was obtained were 
assessed for safety. Pearson’s correlation coefficient was 
used as a measure of linear relationship between tumor and 
mucosa concentrations of methyleneTHF, THF, methyl-
THF, and formylTHF and between tissue concentration and 
plasma PK parameters of the same metabolites.
Plasma concentration versus time data was analyzed 
using individual profiles from patients by non-compart-
mental analysis (NCA) using Phoenix WinNonlin Profes-
sional® version 6.3 (Pharsight Corporation, North Carolina, 
USA) according to internal procedure (SOP PKx101 ver-
sion 1). In addition, graphical presentation of the PD and 
PK/PD data was done using the PhoenixWinNonlin Profes-
sional® software and Microsoft Excel 2013. The area under 
the plasma concentration–time curve from time zero to the 
time of the last quantifiable concentration (AUClast) was 




Demographic data of the included patients, as well as trial 
profile and treatment data, are presented in Table 2. One 
patient randomized to Isovorin® (60 mg/m2) was withdrawn 
prior to administration of study drug due to an adverse 
reaction toward the administered epidural anesthesia. This 
patient was excluded from both per protocol and safety 
analyses. One patient each from the Modufolin® (60 mg/
m2) and the Isovorin® (60 mg/m2) groups were excluded 
from per protocol analysis because the pathological evalu-
ation of the specimens yielded the diagnosis adenoma and 
thus no malignant tissue was available for analysis. These 
two patients were included in the safety analysis.
The total number of AEs, including five serious adverse 
events (SAEs), reported from the study (safety population, 
n = 31) were 24, experienced by 14 patients. As shown 
in Table 2, one patient could experience many AEs on the 
same occasion. For example, one patient in the group who 
received 200 mg/m2 Modufolin® suffered from an anasto-
motic leak 5 days after surgery and hence experienced six 
different AEs, e.g., pyrexia, abdominal pain and vomiting. 
One patient, randomized to Isovorin® (60 mg/m2), died 
of a cardiac arrest 2 days after surgery. This patient was 
included in both per protocol and safety populations since 
the patient was not in violation of the study protocol dur-
ing the collection of plasma and tissue samples. One more 
patient was lost in follow-up 20 months after surgery, cause 
of death unknown. Postoperative complications including 
wound dehiscence, anastomotic leakage, and pulmonary 
embolism were among other SAEs, as presented in Table 
2. None of the AEs/SAEs were considered by the safety 
physician as having any suspected relationship with study 
Table 1  Folate analyte and internal standard transitions used for 
quantification of folates in plasma
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treatment, i.e., neither with Modufolin® nor with Iso-
vorin®. No suspected unexpected serious adverse reaction 
(SUSARs) occurred in this study.
Pharmacodynamics (per protocol population, n = 29)
The differences in magnitude and significance of the analyzed 
folate metabolites after Modufolin® and Isovorin® administra-
tion, respectively, are shown by drug, dose, and metabolite in 
Fig. 2 and Supplementary Table 1. Modufolin® administra-
tion resulted in significantly higher mucosa concentrations 
of methyleneTHF (p < 0.01 at both dose levels) and THF 
(p < 0.05 at 60 mg/m2, p < 0.01 at 200 mg/m2) than did Iso-
vorin®. Higher concentrations of methyleneTHF and THF 
were also observed in tumor tissue after Modufolin® adminis-
tration. The concentration difference in tumor was statistically 
significant in favor for Modufolin® at 200 mg/m2 (p < 0.01 for 
methyleneTHF and p < 0.05 for THF), while significance was 
not reached at the lower dose level for methyleneTHF or THF. 
The methylTHF levels did not differ significantly according 
to treatment, neither in mucosa nor in tumor tissue. The for-
mylTHF levels, on the other hand, were significantly higher 
in both mucosa and tumor tissue of patients treated with Iso-
vorin® as compared to Modufolin®, at both doses.
A statistically significant linear correlation of tumor and 
mucosa concentrations was confirmed for all studied folate 
metabolites after Modufolin® (60 mg/m2) treatment. The 
correlation was significant for methyleneTHF (r = 0.90, 
p < 0.01), THF (r = 0.98, p < 0.001), methylTHF (r = 0.97, 
p < 0.001), and formylTHF (r = 0.76, p < 0.05). No corre-
lation between tumor and mucosa was found for any of the 
metabolites after administration of 200 mg/m2 Modufolin® 
or Isovorin® (60 or 200 mg/m2).
Pharmacokinetics (per protocol population, n = 29)
The lower limit of quantification (LLOQ) for the folate 
metabolites in plasma ranged from 100–250 µg/L. The 
concentration of the folates in plasma samples collected 
5–20 days before surgery, and on the day of surgery 
prior to drug administration, was below the LLOQ. The 
mean plasma concentrations of the folate metabolites 
versus time following Modufolin® and Isovorin® (60 
and 200 mg/m2) treatments are presented in Fig. 3. The 
pharmacokinetics could not be fully evaluated for meth-
yleneTHF and THF after Isovorin® treatment or for for-
mylTHF after Modufolin® treatment because the major 
part of the obtained results for the assessed metabolites 
was below the LLOQ.
Administration of 200 mg/m2 Modufolin® resulted in 
significantly higher plasma Cmax and AUClast of methyl-
eneTHF (p < 0.01) and THF (p < 0.001) than did the same 
dose of Isovorin® (Fig. 4). At the lower dosage, the result-
ing observations of both metabolites were below LLOQ 
for all patients except one in the Isovorin® group, thus a 
statistical test of difference between treatments was not 
performed. The methyleneTHF Cmax ratio of Modufolin® 
to Isovorin® was 113, and the AUClast ratio was 17 at the 
200 mg/m2 dose level. Performing similar calculations at 
the 60 mg/m2 dose level by comparing the mean methyl-
eneTHF values for the Modufolin® group, and the one sin-
gle detectable observation for the Isovorin® group resulted 
in an approximate Cmax ratio of 52 and an AUClast ratio of 
9. The corresponding results for THF were a Cmax ratio of 
23 and an AUClast ratio of 13 at the 200 mg/m2 dose level. 
At 60 mg/m2, the approximate THF Cmax ratio was 15 and 
AUClast 11.
Table 2  Patient demographics, trial profile, and treatment data of the randomized study patients shown by treatment arm
a
 Excluded before drug administration due to reaction to anesthesia, b cardiac arrest, c pulmonary embolism, d myocardial ischemia, e wound 
dehiscence, f anastomotic leakage, g one patient excluded postoperatively as pathology report revealed adenoma, h time measurements in minutes 
with median (range) shown
Treatment Isovorin® Modufolin®
Dosage 60 mg/m2 200 mg/m2 60 mg/m2 200 mg/m2
Primary inclusion (n) 8 8 8 8
Safety population (n) 7a 8 8 8
Gender (M/F, n) 3/4 4/4 4/4 5/3
Mean age (range) 67 (41–82) 80 (66–93) 72 (57–89) 72 (48–88)
AEs (n)/patients (n) 1/1 4/4 9/5 10/4
SAEs (n) 1b 0 2c,d 2e,f
Per protocol population (n) 6g 8 7g 8
Tumor stage (I/II/III, n) 0/3/3 2/5/1 0/3/4 2/3/3
Tumor location (right/left, n) 3/3 6/2 4/3 5/3
Time to vessel ligationh 63 (35–110) 79 (37–124) 70 (37–105) 116 (30–140)
Time from ligation to biopsyh 50 (25–186) 40 (22–136) 38 (27–83) 44 (33–265)
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As in tissues, the methylTHF levels in plasma were in 
the same order of magnitude after Modufolin® and Iso-
vorin® administration. The calculated Cmax and AUClast 
ratios (Modufolin® to Isovorin®) were 0.7 at both dose lev-
els. Following treatment with Isovorin®, formylTHF was 
measured at high levels. Modufolin® on the other hand 
resulted in only one formylTHF observation above LLOQ 
in the 60 mg/m2 group and four in the 200 mg/m2 group. 
Disregarding the relatively few observations for the Modu-
folin® groups, the Cmax and AUClast Modufolin® to Iso-
vorin® ratios were calculated to be 0.01 and 0.0017, respec-
tively, at the high dose (p < 0.01), and 0.026 and 0.0053, 
respectively, at the low dose (p not applicable).
PD and PK correlation
The presence of any linear correlations between tissue con-
centrations and plasma AUClast observations of the different 
folate metabolites was explored for the different treatments. 
One statistically significant linear AUClast correlation was 
identified in the Modufolin® (60 mg/m2) group for meth-
ylTHF in mucosa (r = 0.76, p < 0.05). No further correla-
tions were found for any metabolite or treatment.
Time and demography
There was no statistical difference in folate levels related to 
age, gender, or tumor location. Neither was there any rela-
tion between folate levels and tumor staging and pathology 
although there was a trend of higher folate levels along with 
a worse differentiation grade. Patients who suffered SAEs had 
higher levels of THF in tumor tissue and mucosa (p < 0.05). 
The time between ligation of main blood vessels and removal 
of bowel specimen, thus sampling of biopsy, did not affect the 
folate levels. The time from i.v. bolus of study drug until vessel 
ligation did relate to tissue levels of methyleneTHF (p < 0.05) 
and methylTHF (p < 0.01) with shorter time being associated 
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Fig. 2  Comparison of mean concentrations (including SD) of methyleneTHF, THF, methylTHF, and formylTHF in mucosa and tumor after 60 
or 200 mg/m2 Isovorin® or Modufolin® (n = 29, per protocol population)
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Fig. 3  The mean plasma concentration and SD of methyleneTHF, THF, methylTHF, and formylTHF following 60 and 200 mg/m2 administra-
tion of Isovorin® or Modufolin® at different time points are presented for the per protocol population (n = 29)
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Discussion
The present study showed that significantly higher lev-
els of methyleneTHF were obtained in both tissue biop-
sies and plasma after administration of Modufolin® com-
pared to Isovorin® (Figs. 2, 3, 4). The finding could have 
implications in treatment of colorectal cancer as folate in 
the form of methyleneTHF is necessary in the formation 
of a ternary complex together with TS and the fluorinated 
metabolite of 5-FU, FdUMP [5–7]. The complex provides 
an inhibitory effect on a critical enzymatic pathway, which 
normally generates the necessary nucleotide substrates for 
DNA synthesis (Fig. 1). Thereby, the cell division cycle is 
impeded, and tumor cells can be triggered into apoptosis. 
While treatment efficacy can be difficult to assess in adju-
vant settings, without visible tumor, several studies have 
confirmed that 5-FU-based chemotherapy improves both 
overall and disease-free survival for patients with stage 
III-disease [14]. Also, 5-FU-based chemotherapy has been 
shown to prolong overall survival in palliative settings [5]. 
The regimes have been duly updated with additions of anti-
bodies or newer drugs such as oxaliplatin into more effec-
tive combination therapies [15, 16].
Although well established in use, the optimal LV dosage 
for 5-FU modulation is still not known. Different regimes 
in clinical practice worldwide use doses of LV from 60 to 
500 mg/m2 [17–19]. In Nordic FLV therapy, 60 mg/m2 of 





































MethyleneTHF        THF    MethylTHF    FormylTHF
Isovorin 200 mg/m2 Modufolin 200 mg/m2
Cmax (µg/L)
MethyleneTHF THF     MethylTHF    FormylTHF
AUClast (h*µg/L)








MethyleneTHF  THF     MethylTHF    FormylTHF
MethyleneTHF  THF     MethylTHF   FormylTHF
Isovorin 200 mg/m2 Modufolin 200 mg/m2











(7)(1) (1) (7) (6) (7) (6) (1) (1) (1) (1)(6) (6)(7) (7) (7)
(7) (8) (8) (8) (8) (8) (8) (4) (7) (8) (8) (8) (8) (8) (8) (4)
Fig. 4  Comparison of mean Cmax and AUClast (including SD) of the 
folate metabolites methyleneTHF, THF, methylTHF, and formylTHF 
in plasma following administration of 60 mg/m2 Isovorin® (n = 6), 
200 mg/m2 of Isovorin® (n = 8), 60 mg/m2 of Modufolin® (n = 7), 
or 200 mg/m2 of Modufolin® (n = 8). Numbers within parentheses 
indicate the number of plasma samples that had a folate concentration 
above the lower limit of quantification. aDue to a limited number of 
observations, a p value could not be calculated
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of 5-FU [19]. Due to the low response rates and the omni-
present problem of toxicity all aspects on improvements 
would be of interest. The interest is not diminished by the 
fact that the drugs, in various doses and combinations, are 
commonly used at a great scale worldwide. One potential 
issue with LV to be addressed is the need for its metabolic 
activation. Growing insight in genomics and metabolomics 
leads to the suspicion that all individuals do not respond 
fully to LV as folate supplementation and, therefore, do not 
experience an optimal treatment effect [11, 20, 21]. Hence, 
one ambition has been to develop a distributable form of 
methyleneTHF, which could be used to bypass the enzy-
matic steps needed to convert LV to methyleneTHF. It has 
been argued that response to LV administration is associ-
ated with considerable intra- and interpatient PK variability 
that could be explained by differences in folate metabo-
lism [21–24]. Administration of Modufolin® instead of LV 
might circumvent such metabolic obstacles. Furthermore, 
an abundance of methyleneTHF in the tumor tissue may 
be generated by using Modufolin®, which might lead to an 
increased response to 5-FU-based chemotherapy by stabili-
zation of the ternary complex [11, 25].
As shown in Fig. 2, significantly higher methyleneTHF 
and THF levels were seen in mucosa and tumor tissue after 
administration of 200 mg/m2 Modufolin® compared to Iso-
vorin®, as well as in mucosa at 60 mg/m2 Modufolin®. A 
difference was also seen in tumor tissue at 60 mg/m2 but 
it did not reach statistical significance, possibly due to low 
number of patients in the low dosage arms (Table 2). The 
higher levels of both methyleneTHF and THF in tumor 
and mucosa resulted most probably from the interconver-
sion between these two metabolites [26]. Thus, the pool 
of THF + methyleneTHF in mucosa and tumor tissue 
was dramatically higher after Modufolin®, as compared 
to Isovorin treatment®. This means that the probability of 
reaching an optimal level of the cofactor methyleneTHF is 
higher after administration of Modufolin® compared to Iso-
vorin®. The high interpatient variability in folate concentra-
tions observed in all groups may be linked to differences 
in the activity of enzymes involved in folate-associated 
pathways. For instance, folate polyglutamation, which is 
regulated by the enzymes folylpolyglutamate synthase and 
γ-glutamyl hydrogenase, is known to have a high impact 
on the folate status [27]. Genotype differences between 
individuals may also affect the tissue folate concentration. 
Polymorphisms in the gene methylenetetrahydrofolate 
reductase may be rate-limiting for the transition of meth-
yleneTHF to methylTHF and might partly explain why the 
methylTHF levels did not differ according to the different 
treatments [12, 28–30]. As expected, the formylTHF lev-
els were significantly higher in all tissues after Isovorin® 
as compared to Modufolin® administration. The reason for 
this presumption is that no formylTHF is generated from 
methyleneTHF due to the irreversible conversion of for-
mylTHF to methenylTHF in the reaction catalyzed by the 
enzyme methenyltetrahydrofolate synthetase (Fig. 1). The 
minute amounts of formylTHF detected may result from 
a build-up of endogenous formylTHF due to the excessive 
amounts of methyleneTHF, added in the form of Modu-
folin®, which probably slow down the conversion rate of 
methenylTHF to methyleneTHF.
The present study included colon tumor tissue, which 
could emulate a neoadjuvant treatment situation or that of 
preoperative chemotherapy. The effect on metastasis tis-
sue could reasonably be assumed to be similar in character 
but needs to be addressed and confirmed in clinical stud-
ies. The same theory could be applied to the adjuvant treat-
ment setting, where however studies are difficult to perform 
as there usually is no visible tumor tissue, and the target 
is presumptive circulating tumor cells or micrometastasis. 
The exact mechanism of 5-FU-related toxicity is also not 
totally understood. Therefore, changes in folate supplemen-
tation could warrant safety studies that monitor treatment 
side-effects. There may also be a need to change dosages 
as well as the administration timing, given the pharmacoki-
netic properties of 5-FU.
Although none of the AEs/SAEs were considered to 
have any suspected relationship with study treatment, the 
study is limited in number of patients which makes it hard 
to draw conclusions with certainty. Still, patients who suf-
fered SAEs had higher THF levels in tumor tissue and 
mucosa, and there was one cardiac event in the Modufolin® 
arm. Therefore, it is reasonable to further address the issue 
of safety which, as always, needs to be weighed against 
desired antitumoral effects. While limited in size, the study 
was performed at a single center with all patients treated 
along the same guidelines and all samples obtained in a 
standardized manner by research nurses. The time elapsed 
from vessel ligation to collection of biopsy, with its’ wide 
range, could provide differences. The finding of an asso-
ciation between lower tissue levels of methyleneTHF 
(p < 0.05) and methylTHF (p < 0.01) and shorter time until 
vessel ligation is of importance. This association may relate 
to the pharmacokinetic properties as shown in Fig. 3. An 
early vessel ligation, which cuts off the blood supply, will 
inhibit further folate uptake resulting in lower tissue folate 
levels. In rectal cancer surgery or laparoscopic surgery, the 
ligation is commonly done early. In this study, however, 
the majority of the patients were subjected to open surgery 
with late ligation.
Conclusion
Several studies have shown elevated concentrations of 
reduced folates in blood and tissue after LV administration; 
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however, our study is the first to compare the results with 
those obtained after Modufolin® administration. Sig-
nificantly higher levels of methyleneTHF and THF were 
obtained with Modufolin® as compared to Isovorin®. The 
higher levels could theoretically beneficially affect the for-
mation of the ternary complex consisting of methyleneTHF, 
TS, and FdUMP and, thus, potentially increase the efficacy 
of 5-FU-based chemotherapy. The results stimulate to fur-
ther evaluation of the impact of Modufolin® as a substitute 
or complement to Isovorin® on clinical outcome within dif-
ferent cancer therapy areas.
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